



# Metabolic

## Phoenix Life

### Product Description

Phoenix Metabolic is designed to manage the treatment of Type 2 Diabetes and its Complications by increasing pancreatic function and insulin sensitivity, while improving liver and kidney function. Further reducing neuropathy, neuropathic pain, inflammation and appetite. Product is targeted for Type 2 Diabetes Only.

### Cannabinoid Extract Proprietor Compound

CANNABIDIOL (CBD), CANNABIGEROL (CBG),
>0.3% TETRAHYDRACANNABINOL (THC)
AND OTHER TRACE CANNABINOIDS
A-HUMULENE , B-CARYOPHYLLENE , B-MYRCENE,
LINALOOL , P-CYMENE, A-PINENE, B-PINENE

### Other Ingredients

Medium-chain triglycerides (MCT) derived from coconut, Water, Glycerin, Cannabis Extracts, Kolliphor HS-15, Peppermint Oil.

### Global Distribution Strategy

Phoenix Metabolic has been approved for export globally under the terms of the agreements with the Government of Vanuatu. Due to the formulation, the product is defined under most CBD laws with respect to sales and distribution. Sales are to be completed as part of the provision of National Healthcare Management Agreements (NHMA's), including community health clinics and supply of Phoenix Metabolic.

Online
Due the product being classified as "CBD from Industrial Hemp", this product can be sold Online and exported to over 20 countries. To facilitate this, the product will be made available as Phoenix Metabolic (LE), without specific medical claims within the jurisdictions offered, unless otherwise approved.

Australia
Partner with local licensed producer for distribution under medical cannabis laws. Local clinical trials to be completed in 2022.

Europe
Online distribution under generic CBD classification. NHMA partnerships 2022 and clinical trials to be commenced in 2023.

Global Distribution
Now that 47 countries have legalized medical cannabis, the inter-country trade is starting to expand. Phoenix Life is focused on import and export of its products from company owned and partnered production facilities. Phoenix Metabolic will initially be sold Online & in National Healthcare Management Agreements starting in the Pacific.

United States
Online distribution under hemp CBD classification. Equaliti License partnership. Clinical trials to be commenced late 2021.

Vanuatu
Approved for supply and study. Initial products to be supplied by the USA. Roll-out approved NHMA to commence 2021.

### Medical History and Development Information

Initial Studies with a 65 year old native American woman showed 45% reduction in fasting blood glucose following a 30 day program of the Phoenix Metabolic prototype. Dr Philip Blair, Phoenix Life Diabetes Director observed the results in thousands of patients. The product is designed to be sold in Soft Gel Capsules and Sub-lingual Sprays.

### Clinical Stage

INITIAL CANDIDATE STRAIN / FORMULATION SELECTED
EFFICACY DATA COLLABORATED WITH RESEARCH TEAM
INITIAL PATIENT GROUP SUCCESS
LARGER PATIENT GROUP SUCCESS
FORMALIZED CLINICAL TRIALS
APPROVED FOR SALE IN LOCAL MARKET
EXEMPTION AVAILABLE FOR IMMEDIATE SALES

LEGEND  Completed  Next Step  Not Completed

### Medical Evidence, Citations and other References

US National Library of Medicine - a part of the National Institutes of Health details the following study and abstract More details are available at <https://pubmed.ncbi.nlm.nih.gov/22155112/>  
 2012 Feb; 180(2): 432-442. DOI: 10.1016/j.ajpath.2011.11.003 Am J Pathol. MCID: PMC3349875 PMID: 22155112

#### The Endocannabinoid System and Plant-Derived Cannabinoids in Diabetes and Diabetic Complications

Author: Béla Horváth, Partha Mukhopadhyay, György Haskó, and Pál Pachter

Abstract: Oxidative stress and inflammation play critical roles in the development of diabetes and its complications. Recent studies provided compelling evidence that the newly discovered lipid signaling system (ie, the endocannabinoid system) may significantly influence reactive oxygen species production, inflammation, and subsequent tissue injury, in addition to its well-known metabolic effects and functions. The modulation of the activity of this system holds tremendous therapeutic potential in a wide range of diseases, ranging from cancer, pain, neurodegenerative, and cardiovascular diseases to obesity and metabolic syndrome, diabetes, and diabetic complications. This review focuses on the role of the endocannabinoid system in primary diabetes and its effects on various diabetic complications, such as diabetic cardiovascular dysfunction, nephropathy, retinopathy, and neuropathy, particularly highlighting the mechanisms beyond the metabolic consequences of the activation of the endocannabinoid system. The therapeutic potential of targeting the endocannabinoid system and certain plant-derived cannabinoids, such as cannabidiol and Δ9-tetrahydrocannabinol, which are devoid of psychotropic effects and possess potent anti-inflammatory and/or antioxidant properties, in diabetes and diabetic complications is also discussed.

### Phoenix Life Sciences Pty Ltd

Level 16, No1 Martin Place Sydney Australia

[www.phoenixlife.com](http://www.phoenixlife.com)